Intravenous milrinone in cardiac surgery

Annals of Thoracic Surgery

Volumn 73, Issue 1, 2002, Pages 325-330

  Levy, Jerrold H ^a,b   Bailey, James M ^a,b   Deeb, G Michael ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MILRINONE; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTERY SPASM; CARDIOPULMONARY BYPASS; DRUG EFFECT; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; HEART STROKE VOLUME; HEART SURGERY; HUMAN; HYDROLYSIS; INOTROPISM; INTERNAL MAMMARY ARTERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; VASODILATATION;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; HEART; HEART TRANSPLANTATION; HEMODYNAMIC PROCESSES; HUMANS; MILRINONE; PHOSPHODIESTERASE INHIBITORS; VENTRICULAR FUNCTION;

EID: 0036150096     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(01)02719-9     Document Type: Article

References (42)

1. m) cyclic adenosine monophosphate phosphodiesterase
2. The pharmacokinetics and pharmacodynamics of newer inotropic agents
3. Pharmacokinetics and pharmacodynamics of phosphodiesterase-III inhibitors
4. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery
5. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs
6. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: A multicenter study
7. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. Solutions
8. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure: Dose-response relationships and comparison to nitroprusside
9. Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure
10. Evaluation of a new bipyridine inotropic agent - Milrinone - In patients with severe congestive heart failure
11. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure
12. Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease
13. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone
14. Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. European Multicenter Trial Group
15. Intravenous milrinone following cardiac surgery. II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group
16. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass
17. The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass
18. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery
19. Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass
20. The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery
21. Inhibition of vasoconstriction by phosphodiesterase III inhibitor milrinone in human conduit arteries used as coronary bypass grafts
22. A comparative evaluation of the effects of multiple vasodilators on human internal mammary artery
23. Arterial grafts for coronary artery bypass grafting: Biological characteristics, functional classification, and clinical choice
24. Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries
25. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB)
26. + channels
27. Milrinone: Systemic and pulmonary hemodynamic effects in neonates after cardiac surgery
28. The pharmacokinetics of milrinone in pediatric patients after cardiac surgery
29. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: A rapid test for reversibility of pulmonary hypertension
30. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension
31. Use of milrinone in cardiac surgical patients
32. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension
33. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent
34. Effect of oral milrinone on mortality in severe chronic heart failure: The PROMISE Study Research Group
35. Electrophysiology of phosphodiesterase inhibitors
36. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents
37. Amrinone-associated thrombocytopenia: Pharmacokinetic analysis
38. Amrinone-induced thrombocytopenia
39. The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure
40. Platelet function alterations during cardiac surgery
41. A comparison of the effects of three positive inotropic agents (amrinone, milrinone and medorinone) on platelet aggregation in human whole blood
42. The effects of milrinone on platelets in patients undergoing cardiac surgery